Alex Therapeutics' digital anxiety therapy trial yields positive outcomes

In a groundbreaking announcement, Alex Therapeutics and Vicore Pharma revealed positive results from the COMPANION study assessing the efficacy of Almee, a 9-week digital cognitive behavioural therapy (CBT) app designed to address anxiety. The study enrolled 108 participants diagnosed with pulmonary fibrosis, a chronic and fatal disease, and the results indicated a notable 2.7-point improvement in GAD-7 anxiety scores compared to the control group. 

This improvement exceeded the clinically meaningful threshold of 1.8, showcasing the potential of Almee to significantly alleviate anxiety levels for individuals coping with pulmonary fibrosis. Additionally, the study measured quality of life using the K-BILD, reporting a 4.4-point improvement, with the psychological domain showing an impressive 6.5-point enhancement.

The COMPANION study's positive outcomes are particularly noteworthy as they signify the success of a tailored, evidence-based CBT intervention delivered through a user-friendly mobile app. The collaboration between Alex Therapeutics and Vicore Pharma is emphasised as a pivotal factor in achieving these promising results. The study's Principal Investigator, Dr. Maureen Horton, expressed optimism about the clinical benefits of a digital CBT tool in addressing the mental health burden associated with pulmonary fibrosis. The findings suggest that Almee could play a vital role alongside existing molecular therapies, offering a holistic approach to improving the well-being of individuals grappling with pulmonary fibrosis.

John Drakenberg, CEO of Alex Therapeutics, commented on the groundbreaking nature of the results and highlighted the impact of partnerships in designing patient-facing apps that positively influence behaviour and enhance patient outcomes. Ahmed Mousa, Chief Executive Officer of Vicore, echoed the sentiment, emphasising the potential for Almee to complement molecular therapies and contribute significantly to addressing the multifaceted challenges faced by individuals suffering from pulmonary fibrosis.